Alembic Pharmaceuticals is targeting to raise its Ebitda margins to 18-20% over the next couple of years, according to the company's Managing Director, Pranav Amin. The company is hopeful of improving its margins due to enhanced capacity and production ramp-up in the second half of the current financial year.
“We're doing pretty okay on capacities. Some are completely full, while others are ramping up. The other plants will ramp up as well in the second half. And that is why you will see a margin improvement, not just the second half, but moving forward from the current 17% Ebitda margins. I believe that over the next couple of years, we will inch closer to the 18, 19, 20% kind of margins,” he said during a conversation with NDTV Profit on Tuesday.
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
He highlighted the company's strategic focus on international generics, cost efficiencies, and a rich product pipeline to drive future expansion.
“We have guidance for capex of about Rs 400 crore. Most of this was either maintenance or de-bottlenecking,” he said.
Addressing investor concerns about the challenging US market, Amin acknowledged that pricing pressure "continues to remain". However, he explained that the company is successfully countering this trend.
“The US side, the pricing pressure, continues to remain. I think we're just countering that by higher volumes and adding more products that help us balance it,” he said.
The generics segment in the rest of the world (excluding the US) has shown consistent quarter-on-quarter growth over the past 15-20 quarters, emerging as a high-margin opportunity.
“Strategically, we are trying to build up the rest of the world generics business. It's a good margin business. We focused on a few territories; we're expanding to more. That business has done well,” the top executive said.
A significant portion of Alembic Pharma's R&D spend over the last few years has been allocated toward the US, resulting in a "much richer pipeline". The company is planning some “high-value launches” in the US market over the next 12-18 months, including complex injectables, peptides and ophthalmic products, a segment that is currently performing very well.
Shares of Alembic Pharma closed 2.79% higher at Rs 950 apiece on the NSE, while the benchmark Nifty50 ended 0.64% lower at 25,597.65.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.